Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Official title

A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Study identification

NCT ID

NCT06616584

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 2, Phase 3

Lead sponsor

SWOG Cancer Research Network

Network

Enrollment

378 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

May 21, 2025

Primary completion

Dec 30, 2027

Completion

Dec 30, 2028

Last update posted

May 4, 2026

2025 – 2028

United States locations

U.S. sites

386

U.S. states

42

U.S. cities

319

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.